Literature DB >> 21519849

Identification of SNF2h, a chromatin-remodeling factor, as a novel binding protein of Vpr of human immunodeficiency virus type 1.

Daiki Taneichi1, Kenta Iijima, Akihiro Doi, Takayoshi Koyama, Yuzuru Minemoto, Kenzo Tokunaga, Mari Shimura, Shigeyuki Kano, Yukihito Ishizaka.   

Abstract

Vpr, an accessory gene of human immunodeficiency virus type 1, encodes a virion-associated nuclear protein that plays an important role in the primary viral infection of resting macrophages. It has a variety of biological functions, including roles in a cell cycle abnormality at G(2)/M phase, apoptosis, nuclear transfer of preintegration complex, and DNA double-strand breaks (DSBs), some of which depend on its association with the chromatin of the host cells. Given that DSB signals are postulated to be a positive factor in the viral infection, understanding the mode of chromatin recruitment of Vpr is important. Here, we identified SNF2h, a chromatin-remodeling factor, as a novel binding partner of Vpr involved in its chromatin recruitment. When endogenous SNF2h protein was extensively downregulated by SNF2h small interfering RNA (siRNA), the amount of Vpr loaded on chromatin decreased to about 30% of the control level. Biochemical analysis using a mutant Vpr suggested that Vpr binds SNF2h via HFRIG (amino acids 71-75 depicted by single letters) and the Vpr mutant lacking this motif lost the activity to induce DSB-dependent signals. Consistently, Vpr-induced DSBs were attenuated by extensive downregulaion of endogenous SNF2h. Based on these data, we discuss the role of DSB and DSB signals in the viral infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519849     DOI: 10.1007/s11481-011-9276-5

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  50 in total

1.  Comprehensive analysis of the ICEN (Interphase Centromere Complex) components enriched in the CENP-A chromatin of human cells.

Authors:  Hiroshi Izuta; Masashi Ikeno; Nobutaka Suzuki; Takeshi Tomonaga; Naohito Nozaki; Chikashi Obuse; Yasutomo Kisu; Naoki Goshima; Fumio Nomura; Nobuo Nomura; Kinya Yoda
Journal:  Genes Cells       Date:  2006-06       Impact factor: 1.891

2.  HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection.

Authors:  M A Vodicka; D M Koepp; P A Silver; M Emerman
Journal:  Genes Dev       Date:  1998-01-15       Impact factor: 11.361

3.  Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase.

Authors:  Alan Lau; Karra M Swinbank; Parvin S Ahmed; Debra L Taylor; Stephen P Jackson; Graeme C M Smith; Mark J O'Connor
Journal:  Nat Cell Biol       Date:  2005-04-17       Impact factor: 28.824

4.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 5.  The comet assay: a comprehensive review.

Authors:  D W Fairbairn; P L Olive; K L O'Neill
Journal:  Mutat Res       Date:  1995-02       Impact factor: 2.433

6.  HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination.

Authors:  C Nakai-Murakami; M Shimura; M Kinomoto; Y Takizawa; K Tokunaga; T Taguchi; S Hoshino; K Miyagawa; T Sata; H Kurumizaka; A Yuo; Y Ishizaka
Journal:  Oncogene       Date:  2006-09-18       Impact factor: 9.867

7.  Identification of a novel antibody associated with autoimmune pancreatitis.

Authors:  Luca Frulloni; Claudio Lunardi; Rita Simone; Marzia Dolcino; Chiara Scattolini; Massimo Falconi; Luigi Benini; Italo Vantini; Roberto Corrocher; Antonio Puccetti
Journal:  N Engl J Med       Date:  2009-11-26       Impact factor: 91.245

8.  Ataxia-telangiectasia-mutated (ATM) protein can enhance human immunodeficiency virus type 1 replication by stimulating Rev function.

Authors:  Yasuo Ariumi; Didier Trono
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

9.  Vpr in plasma of HIV type 1-positive patients is correlated with the HIV type 1 RNA titers.

Authors:  Shigeki Hoshino; Binlian Sun; Mitsuru Konishi; Mari Shimura; Tatsuya Segawa; Yoshiaki Hagiwara; Yoshio Koyanagi; Aikichi Iwamoto; Jun-Ichi Mimaya; Hiroshi Terunuma; Shigeyuki Kano; Yukihito Ishizaka
Journal:  AIDS Res Hum Retroviruses       Date:  2007-03       Impact factor: 2.205

10.  The Williams syndrome transcription factor interacts with PCNA to target chromatin remodelling by ISWI to replication foci.

Authors:  Raymond A Poot; Ludmila Bozhenok; Debbie L C van den Berg; Søren Steffensen; Fernando Ferreira; Margaret Grimaldi; Nick Gilbert; Joao Ferreira; Patrick D Varga-Weisz
Journal:  Nat Cell Biol       Date:  2004-11-14       Impact factor: 28.824

View more
  5 in total

1.  Cell signaling pathways and HIV-1 therapeutics.

Authors:  Johnny J He
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-30       Impact factor: 4.147

2.  DNA damage enhances integration of HIV-1 into macrophages by overcoming integrase inhibition.

Authors:  Takayoshi Koyama; Binlian Sun; Kenzo Tokunaga; Masashi Tatsumi; Yukihito Ishizaka
Journal:  Retrovirology       Date:  2013-02-21       Impact factor: 4.602

3.  HIV-1 Vpr induces the degradation of ZIP and sZIP, adaptors of the NuRD chromatin remodeling complex, by hijacking DCAF1/VprBP.

Authors:  Claire Maudet; Adèle Sourisce; Loïc Dragin; Hichem Lahouassa; Jean-Christophe Rain; Serge Bouaziz; Bertha Cécilia Ramirez; Florence Margottin-Goguet
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

4.  Structural alteration of DNA induced by viral protein R of HIV-1 triggers the DNA damage response.

Authors:  Kenta Iijima; Junya Kobayashi; Yukihito Ishizaka
Journal:  Retrovirology       Date:  2018-01-16       Impact factor: 4.602

Review 5.  Vpr and Its Cellular Interaction Partners: R We There Yet?

Authors:  Helena Fabryova; Klaus Strebel
Journal:  Cells       Date:  2019-10-24       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.